ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1416

Analysis of Cardiac Involvement in Patients with Amyloid a (AA) Amyloidosis Due to Rheumatoidarthritis

Daisuke Kobayashi1, Satoshi Ito1, Satoru Kodama1, Akira Murasawa1, Ichiei Narita2 and Kiyoshi Nakazono1, 1Niigata Rheumatic Center, Shibata, Japan, 2Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Amyloidosis, morbidity and mortality and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose Rheumatoid arthritis (RA) is one of the major causes of amyloid A (AA) amyloidosis. The major organs affected are the kidneys and gastrointestinal (GI) tract. Although cardiac amyloidosis is the principal cause of death in patients with amyloid L amyloidosis, significant cardiac involvement in AA amyloidosis is thought to be rare. On the other hand, the survival rate of hemodialysis patients with AA amyloidosis associated with RA has been shown to be low, and our previous study revealed that cardiac failure accounted for more than half of the mortality in these patients. The purpose of this analysis was to clarify the cardiac involvement and its clinical significance in patients with RA-associated AA amyloidosis.

Methods Twenty-seven RA patients (4 males, 23 females) with AA amyloidosis who were followed up at Niigata Rheumatic Center between April 2007 and March 2014 were enrolled. Each patient fulfilled the 1987 American College of Rheumatology criteria for RA. All patients had undergone GI tract biopsies, and had been confirmed to have reactive AA amyloidosis by pathological examination. The patients’ background data and echocardiographic features were analyzed retrospectively. Differences were assessed by Mann-Whitney U test*, Fisher’s exact test#, and log rank test**, and differences at p <0.05 were considered statistically significant.

Results The median age was 71 [range, 48-89] yr, the period between the onset of RA and echocardiographic examination was 20 [2-41] yr, and the period between the onset of AA amyloidosis and echocardiographic examination was 1007 [20-6458] day. Echocardiography showed that the left ventricular (LV) posterior wall thickness was 11.0 [7.4-17.0] mm, with an interventricular septal thickness of 10.5 [5.5-14.2] mm, and an ejection fraction (EF) of 72.1% [32.3-85.4%]. Thirteen patients with LV wall thickness exceeded 11.0 mm were assigned to a LV hypertrophy (LVH) group, and their clinical features were compared with a normal group (n=14). Fatalities in the LVH group vs normal group were 7 vs 0 at two year after echocardiography and 9 vs 2 at the last observation. Kaplan-Meier survival curves showed a significant association with reduced survival in the LVH group (p=0.039**). There were no significant differences between the LVH group and the normal group at the baseline in terms of patient age (p=0.512*), duration of RA (p=0.627*), serum albumin level (p=0.92*), estimated glomerular filtration rate (eGFR) (p=0.094*), disease activity score in 28 Joints based on erythrocyte sedimentation rate (p=0.19*), modified Health Assessment Questionnaire score (p=0.77*), and echocardiogram EF (p=0.21*). Patients in the LVH group had a higher systolic blood pressure (133 [116-160] vs 120.5 [110-142] mmHg, p=0.039*), in spite of higher usage of antihypertensive agents (12 vs 3, respectively, p<0.001#). Although the LVH group appeared to have a lower eGFR, there was no significant difference in survival rate between the patients whose eGFR was under 45 ml/min/1.73 m2 (n=12) and the others (n=15) (p=0.52**).

Conclusion Thickening of the LV wall is a notable cardiac feature of patients with AA amyloidosis and is strongly suspected to contribute to their poor prognosis.


Disclosure:

D. Kobayashi,
None;

S. Ito,
None;

S. Kodama,
None;

A. Murasawa,
None;

I. Narita,
None;

K. Nakazono,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-cardiac-involvement-in-patients-with-amyloid-a-aa-amyloidosis-due-to-rheumatoidarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology